See more : GeneTether Therapeutics Inc. (GTTX.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Sol-Gel Technologies Ltd. (SLGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sol-Gel Technologies Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hakuyosha Company, Ltd. (9731.T) Income Statement Analysis – Financial Results
- Helios Underwriting plc (HUW.L) Income Statement Analysis – Financial Results
- Falcon Oil & Gas Ltd. (FO.V) Income Statement Analysis – Financial Results
- Tailam Tech Construction Holdings Limited (6193.HK) Income Statement Analysis – Financial Results
- SWIGGY LIMITED (SWIGGY.BO) Income Statement Analysis – Financial Results
Sol-Gel Technologies Ltd. (SLGL)
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.55M | 3.88M | 31.27M | 8.77M | 22.90M | 129.00K | 174.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 300.00K | 359.00K | 300.00K | 0.00 |
| Gross Profit | -21.99M | -8.80M | 10.89M | -19.14M | -17.67M | -28.02M | -126.00K | -359.00K | -300.00K | 0.00 |
| Gross Profit Ratio | -1,414.86% | -226.60% | 34.83% | -218.24% | -77.17% | -21,718.60% | -72.41% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.54M | 12.68M | 20.38M | 27.91M | 40.58M | 28.15M | 25.81M | 17.02M | 7.18M | 2.93M |
| General & Administrative | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.37M | 7.45M | 8.45M | 11.09M | 8.28M | 5.50M | 6.00M | 3.73M | 2.46M | 1.88M |
| Other Expenses | -55.00K | 0.00 | -524.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Cost & Expenses | 30.86M | 20.13M | 28.31M | 39.00M | 48.85M | 33.65M | 31.81M | 20.76M | 9.65M | 4.81M |
| Interest Income | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 40.00K |
| Interest Expense | 0.00 | 1.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 342.00K | 562.00K | 880.00K | 946.00K | 887.00K | 762.00K | 300.00K | 359.00K | 300.00K | 225.00K |
| EBITDA | -28.96M | -15.68M | 3.84M | -29.29M | -25.06M | -32.76M | -31.16M | -20.40M | -9.35M | -4.58M |
| EBITDA Ratio | -1,863.77% | -403.86% | 9.48% | -344.69% | -109.43% | -25,394.57% | -17,909.20% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.31M | -16.24M | 2.08M | -30.23M | 25.95M | -33.52M | -31.63M | -20.76M | -9.65M | -4.81M |
| Operating Income Ratio | -1,885.78% | -418.34% | 6.66% | -344.69% | 113.30% | -25,985.27% | -18,179.89% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.07M | 1.32M | 257.00K | 943.00K | 1.37M | 1.32M | 65.00K | -15.00K | -13.00K | -40.00K |
| Income Before Tax | -27.24M | -14.92M | 3.22M | -29.29M | -24.58M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Income Before Tax Ratio | -1,752.77% | -384.32% | 10.30% | -333.94% | -107.30% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -1.14M | -1.89M | 33.00K | -1.32M | -65.00K | 15.00K | 13.00K | 0.00 |
| Net Income | -27.24M | -13.60M | 4.36M | -27.40M | -24.61M | -32.20M | -31.57M | -20.77M | -9.66M | -4.85M |
| Net Income Ratio | -1,752.77% | -350.30% | 13.94% | -312.40% | -107.44% | -24,963.57% | -18,142.53% | 0.00% | 0.00% | 0.00% |
| EPS | -1.01 | -0.59 | 0.19 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| EPS Diluted | -1.01 | -0.59 | 0.18 | -1.21 | -1.26 | -1.80 | -1.76 | -1.77 | -0.82 | -1.81 |
| Weighted Avg Shares Out | 27.09M | 23.13M | 23.06M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
| Weighted Avg Shares Out (Dil) | 27.09M | 23.13M | 23.57M | 22.57M | 19.53M | 17.87M | 17.99M | 11.74M | 11.74M | 2.68M |
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sol-Gel Technologies Ltd. (SLGL) Reports Q3 Loss, Tops Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.13.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholders Phase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activated SGT-210 proof-of-concept study in patients suffering from Darier disease...
SolGel Technologies (SLGL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for SolGel Technologies (SLGL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for...
All You Need to Know About SolGel Technologies (SLGL) Rating Upgrade to Strong Buy
SolGel Technologies (SLGL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UPDATE: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by...
Sol-Gel Technologies Ltd. (SLGL) Surpasses Q2 Earnings and Revenue Estimates
Sol-Gel Technologies Ltd. (SLGL) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share.
Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026 Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites activated; Top-line results are expected by...
Sol-Gel Technologies Announces Management Realignment
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with...
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau, Taiwan and Israel, for a total consideration...
Source: https://incomestatements.info
Category: Stock Reports